unknown by Zenati, Marco & Cohen, Howard A.
use. The analogy of a comparison between “unproven herbal
approach versus tested scientific study” must be considered.
Gerald D. Buckberg, MD
Department of Cardiothoracic Surgery
UCLA Medical Center
Room 62-258
Box 951741
Los Angeles, CA 90095-1741
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Emerging new concepts of myocardial laser revas-
cularization
To the Editor:
Zenati, Cohen, and Griffith1 express support for the devel-
opment of centers in which different revascularization proce-
dures would be performed in the same patient by teams com-
posed of interventional cardiologists and cardiovascular
surgeons. Will myocardial laser revascularization (MLR),
either percutaneous or surgical, find its place in such team-
work when its original idea of perfusion of the left ventricle
from its cavity is no longer valid?2
In the meantime, a new concept trying to explain why MLR
has been beneficial to some patients has emerged: angiogen-
esis as a nonspecific response of the myocardium to injury.
All the same, this concept is usually considered unfit to serve
as a vehicle for MLR because this procedure leads only rarely
to the improvement of objective parameters such as cardiac
perfusion and function, exercise capacity, and survival.2
Before MLR is abandoned, we must be sure that it (1) has
been used correctly and (2) was applied to suitable patients. I
am afraid this has not always been the case.
Angiogenesis fulfills its purpose only if a source of oxy-
genated blood is available. This condition provided, angio-
genesis diminishes ischemia solely if it leads to the develop-
ment of collateral vessels linking the ischemic with the
well-perfused myocardium.3 In agreement with these con-
cepts, cardiomyocyte death induced by MLR would lead to
inflammatory angiogenesis and wound healing reaction.
Newly formed capillaries would connect blood vessels of the
lased ischemic region with blood vessels of neighboring well-
perfused areas. The angiogenesis would not subside after the
healing of laser channels because friction between noncom-
pliant laser channel scars and the contractile surrounding
myocardium would induce continuous injury and inflamma-
tion.4 New capillaries would not regress because of a pressure
gradient between the well-perfused myocardium and the
ischemic region.3 The remodeling of capillary-sized collater-
als into arterioles and arteries would complete the revascular-
ization, that is, the collateralization of the ischemic region.
Contrary to the above hypotheses, MLR has been used
mostly in patients with diffuse multivessel end-stage coro-
nary artery disease with contraindications to percutaneous
transluminal coronary angioplasty and coronary artery
bypass grafting. It is obvious that angiogenesis is of no use if
the whole ventricle is ischemic. On the contrary, the use of
MLR in combination with coronary artery bypass grafting
and/or coronary angioplasty (as it would be practiced in inte-
grated revascularization centers) is an excellent idea. The
conventional techniques would provide the source of well-
oxygenated blood wherever possible, and MLR would facili-
tate the development of collateral vessels in the areas inac-
cessible for traditional revascularization. It is worthy of note
that Mirhoseini, Shelgikar, and Cayton,5 the inventors of
MLR, used this method in combination with coronary artery
bypass grafting when they started to apply it to patients. This
undoubtedly explains their success. Recently, Trehan and col-
leagues6 used MLR in combination with minimally invasive
coronary artery bypass grafting and claimed excellent results.
All this suggests that MLR, if used in conjunction with other
methods of revascularization, will find its place in the thera-
peutic armamentarium used against ischemic heart disease.
Jiri T. Beranek
4101 S Wappel Dr
Columbia, MO 65203
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Reply to the Editor:
We enjoyed reading Beranek’s comments and discussion of
myocardial laser revascularization (MLR). Our concept of
integrated coronary revascularization is in constant evolution,
as new techniques become available both to the cardiac sur-
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geon and to the interventional cardiologist. Regarding the
combination of MLR and conventional bypass operations,
Allen and associates1 recently presented favorable results of a
multicenter prospective randomized study; therefore we agree
that the combination of revascularization techniques using
minimally invasive off-pump surgery and MLR (percuta-
neous or surgical) will have a role in the future for selected
subsets of patients. This multimodality collaborative approach
to myocardial revascularization is currently being applied
increasingly at our institution, and we agree with Mack’s
recent forecast2 that in 10 years 50% of all cardiac operations
will be combined with a catheter-based procedure. To quote
Rihal and Yusuf,3 perhaps the relevant clinical question is not
which mode of treatment is best, but which combinations of
treatments, in what sequence, are appropriate for a specific
patient at a specific point in his or her clinical course.
Marco Zenati, MD 
Director, Minimally Invasive Cardiac Surgery Program
Howard A. Cohen, MD 
Director, Cardiac Clinical Services
Cardiovascular Institute
University of Pittsburgh Medical Center
Pittsburgh, PA 15213
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Aortic arch reconstruction without circulatory
arrest
To the Editor:
We read with great interest the discussion of a modified
perfusion technique during Norwood reconstruction by
Pigula, Siewers, and Nemoto1 and can offer some modifica-
tions that will further improve on this technique. In their
report, the authors describe a technique to provide regional
cerebral perfusion through the distal end of a partially con-
structed 3.5-mm polytetrafluoroethylene shunt to provide
cerebral flow through the innominate artery during the “cir-
culatory arrest” period. The authors monitor regional cerebral
oxyhemoglobin saturation and relative cerebral blood volume
index and demonstrate that the collateral network provides
seemingly adequate cerebral blood flow while the arch is
being reconstructed. Further supporting the presence of an
extensive collateral network, the authors note the need for an
aortic crossclamp on the distal aorta to prevent the collateral
flow from flooding the operative field.
We have used a similar technique for Norwood-type recon-
struction in hypoplastic left heart syndrome and describe
some differences in technique that offer further benefit. In
contrast to Pigula, Siewers, and Nemoto, our first maneuver
after a short period of surface cooling (to 34°C), sternotomy,
and heparinization is to create the proximal end of a 3.5-mm
polytetrafluoroethylene shunt at the base of the right subcla-
vian artery. This shunt is left long and is cannulated with the
arterial inflow cannula (8F, Research Medical, Inc, Salt Lake
City, Utah). Cardiopulmonary bypass is then initiated with
bicaval venous cannulation and the pulmonary arteries are
controlled with snares. The patient is cooled to 18°C over 20
minutes.
The advantage of this modification in technique is that a
large portion of the procedure can then be performed during
full cardiopulmonary bypass while cooling. Specifically,
using the shunt as the arterial inflow leaves the aortic arch
and ductus arteriosus free of cannulas. Consequently, the
ductus can be ligated and divided, after which the main pul-
monary artery can be divided and the pulmonary artery defect
closed with a small polytetrafluoroethylene patch.
Furthermore, the right atrium can then be opened and the atri-
al septectomy performed. There is no possibility of ejecting
air in cases of aortic atresia due to the valve atresia and the
fact that the main pulmonary artery is divided. By this time,
the patient has been nearly completely cooled to 18°C. A
“drop in” sucker can be left in the right atrium to keep the
field clear.
Up to this point, the patient has been maintained on full
cardiopulmonary bypass without any myocardial ischemia.
Flow can be momentarily interrupted and cardioplegic solu-
tion infused through the arterial inflow cannula with the
descending aorta clamped and the subclavian and carotid
arteries temporarily occluded. Cardiopulmonary bypass is
then resumed at 30 to 60 mL/min with the base of the innom-
inate artery occluded and the distal subclavian and right
carotid artery snares released. We monitor pressure in the
right radial artery and maintain it at 20 to 30 mm Hg. The
arch reconstruction is then completed and, like Pigula,
Siewers, and Nemoto, we use a crossclamp on the distal aorta
to avoid collateral flow from obscuring the operative field.
On completion of the arch reconstruction, the neo-aortic
arch is cannulated with a second cannula and the arch
deaired. Arterial inflow is then transferred to the new cannu-
la and full cardiopulmonary bypass resumed. While the
patient is being rewarmed, the distal end of the 3.5-mm shunt
is trimmed and an anastomosis completed with the right pul-
monary artery.
The chief advantage of these modifications is better time
efficiency during the case. All the portions of the repair outside
the aortic arch are performed during the cooling period with
full cardiopulmonary bypass and without cardioplegic arrest.
Myocardial ischemia and regional cerebral perfusion are limit-
ed to only the period during which the ascending aorta is open.
This shortened period of systemic “circulatory arrest” aug-
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